Targeted Degradation of Kinases: PROTAC Tools for Undruggable Kinase Targets

The Kinase Problem in Drug Discovery

Kinases are among the most widely pursued targets in drug discovery, yet they present unique challenges. Traditional kinase inhibitors work by occupying the ATP binding pocket, preventing phosphorylation. This approach has yielded valuable therapeutics, but it comes with limitations: inhibition is incomplete, mutations conferring resistance emerge readily, and loss of scaffolding functions – kinases’ non-catalytic signaling roles – cannot be addressed by inhibition alone.

Proteolysis targeting chimeras (PROTACs) targeting kinases represent a fundamentally different approach: complete removal of the protein from the cell.

Kinase PROTACs: Degradation vs Inhibition

Why degrade a kinase instead of just inhibiting it? The advantages are substantial.

Complete Loss of Function: Inhibitors leave the kinase protein intact, maintaining residual catalytic activity and all non-catalytic roles. Degradation completely eliminates the protein, ensuring comprehensive functional loss.

Overcoming Resistance: One of the major clinical challenges with kinase inhibitors is the emergence of resistance mutations. Patients treated with JAK inhibitors, EGFR inhibitors, or BCR-ABL inhibitors eventually develop mutations that confer reduced drug binding. Because PROTACs work through an entirely different mechanism – recruiting the kinase to an E3 ubiquitin ligase – they can often maintain activity against resistant mutants. A kinase with a point mutation causing inhibitor resistance may still be recognized by a PROTAC warhead.

Scaffolding Function Elimination: Many kinases function not only as catalytic enzymes but also as scaffolds organizing signaling complexes. Inhibition cannot address these non-catalytic roles. Degradation eliminates both functions simultaneously. This is particularly important for kinases like RAF, which function partly through their kinase activity and partly through assembly of signaling complexes.

Reduced Compensation: Cells often compensate for inhibited kinases through upregulation of related family members. Complete protein removal prevents this adaptive response more effectively than inhibition.

Kinase PROTACs: From Concept to Practice

The first kinase-targeting PROTACs demonstrated the potential of this approach. ARV-471, targeting estrogen receptor for degradation, reached clinical trials. BET bromodomain-containing proteins (which have kinase-like functions) were successfully targeted by dBET1 and other PROTACs. More recently, true kinase degraders have moved into development.

Some prominent examples include:

• JAK PROTACs: Multiple PROTAC-based JAK degraders have been synthesized, showing superior activity against JAK-mutant cell lines compared to JAK inhibitors
• EGFR PROTACs: Targeting EGFR with PROTACs provides degradation of wild-type EGFR and importantly, several clinically relevant EGFR mutants
• CDK4/6 PROTACs: Cell cycle kinases CDK4 and CDK6 have been targeted with PROTACs, showing enhanced anti-proliferative effects versus inhibition
• SRC Family Kinase PROTACs: The SRC family, important in both normal and transformed cells, has been extensively explored with PROTAC-based degraders

Designing Kinase-Targeting PROTACs

Effective kinase PROTACs require careful design choices. Most leverage existing kinase inhibitors as warheads – molecules already known to bind the ATP pocket with high affinity and selectivity. The kinase inhibitor portion is then connected via a linker to an E3 ligase ligand.

The best kinase PROTACs maintain the selectivity of the original inhibitor warhead while adding E3 ligase engagement. This dual selectivity – selectivity for the target kinase and selectivity for the recruited E3 ligase (usually CRBN or VHL) – helps minimize off-target degradation of other proteins.

Linker length and chemistry are particularly important for kinase PROTACs. Different kinases have different structural features that influence optimal ternary complex geometry. Immunomart’s PROTAC research compounds include diverse kinase-targeting variants, allowing systematic exploration of these design parameters.

E3 Ligase Selection for Kinase Degradation

The E3 ligase recruited by a PROTAC warhead profoundly influences degradation selectivity and efficiency. Cereblon (CRBN) and von Hippel-Lindau (VHL) are the two most commonly used E3 ligases in PROTAC development.

CRBN-recruiting PROTACs: These generally produce more dramatic degradation effects and lower DC50 values (concentration producing 50% degradation). However, CRBN recruitment can result in degradation of non-target proteins in some cellular contexts.

VHL-recruiting PROTACs: VHL-based PROTACs often show greater selectivity, degrading primarily the target kinase without collateral damage. The trade-off is sometimes higher DC50 values and more gradual degradation kinetics.

Emerging E3 ligases like MDM2, IAPs, and others are being explored, potentially offering new selectivity profiles for challenging kinase targets.

Cell Cycle and Proliferation Control

Cell cycle kinases represent particularly compelling PROTAC targets. CDK4/6 inhibitors are established cancer therapeutics, but resistance emerges through multiple mechanisms. CDK4/6-targeting PROTACs show enhanced anti-proliferative effects in some resistant contexts.

Kinases regulating G1/S transition (like CDK2) and other cell cycle points are being explored with PROTACs. The complete removal of these kinases prevents compensatory pathway activation more effectively than inhibition alone.

Overcoming Undruggable Kinase Targets

Some kinases have proven resistant to traditional inhibitor development. These “undruggable” kinases may have shallow ATP-binding pockets, lack defined active sites, or couple active site binding to promiscuous off-target effects. PROTACs offer a different angle.

Because PROTACs work through proximity-induced ubiquitination rather than occupancy-dependent inhibition, they can sometimes target proteins for degradation even when high-affinity inhibitors cannot be developed. This has opened previously intractable targets to degradation-based therapeutics.

Kinase PROTACs in Resistant Cancers

Cancer cells develop resistance to kinase inhibitors through multiple mechanisms: point mutations affecting drug binding, amplification of kinase genes, activation of bypass pathways, and others. Kinase PROTACs address several of these resistance mechanisms simultaneously.

In resistant leukemia models, JAK inhibitor-resistant mutations remain susceptible to JAK PROTACs. In EGFR-mutant lung cancer, EGFR-targeting PROTACs degrade common resistance mutations more effectively than EGFR inhibitors. These examples demonstrate the practical advantages of kinase degradation over inhibition in the context of drug resistance.

Temporal Control and Reversibility

An often-overlooked advantage of kinase PROTACs is temporal control. While most PROTACs cause relatively rapid and sustained degradation, combining PROTAC treatment with removal of the compound allows kinase re-synthesis and function restoration. This enables more sophisticated experimental designs and potentially therapeutic regimens that intermittent PROTAC administration could optimize.

Exploring Kinase Degraders for Your Research

Immunomart provides research-grade kinase degraders and PROTAC scaffolds for scientists building degradation-based assays and cell models. Whether you’re investigating a novel kinase target, exploring resistance mechanisms, or developing degradation-based screens, having access to diverse kinase PROTACs accelerates discovery.

The transition from kinase inhibition to kinase degradation represents a maturing field with substantial clinical potential. Understanding the distinctions between these approaches and their complementary advantages positions researchers to choose the most appropriate tool for each biological question.